Comparative Safety and Pharmacokinetic Evaluation of Three Oral Selenium Compounds in Cancer Patients
Sign Up to like & getrecommendations! Published in 2018 at "Biological Trace Element Research"
DOI: 10.1007/s12011-018-1501-0
Abstract: Selenium (Se) compounds have demonstrated anticancer properties in both preclinical and clinical studies, with particular promise in combination therapy where the optimal form and dose of selenium has yet to be established. In a phase… read more here.
Keywords: selenium compounds; safety pharmacokinetic; evaluation; selenium ... See more keywords
Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.2510
Abstract: 2510Background: SAR439459 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. In preclinical models, combining SAR439459 with an anti-PD-1 showed improved anti-tumor act... read more here.
Keywords: pharmacokinetic pharmacodynamic; sar439459; pharmacodynamic results; dose escalation ... See more keywords
Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.3574
Abstract: 3574Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA repeats) and UGT1A1*93 (SNP -3156G > A) are significantl... read more here.
Keywords: pharmacokinetic analysis; genotype guided; ugt1a1 genotype; safety pharmacokinetic ... See more keywords